Granted Patent
B2
US 7,666,872 · App. 10/590,992 · Granted Feb 23, 2010
Use for PDE5 inhibitors
Assignee:
NYCOMED GmbH
View Patent ↗
Loading inventors, assignments & file history…
Abstract
The present invention is concerned with the use of PDE5 inhibitors in medicine.
Claims (1)
1. A method of treatment of sepsis associated encephalopathy in a patient afflicted with such disease comprising the step of administering a pharmacologically tolerable and therapeutically effective amount of 5-[2-ethoxy-5-(4-methyl-1-piperazinylsulphonyl)phenyl]-1-methyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one (sildenafil) or, a pharmaceutically acceptable salt thereof, to the patient.
Assignments (6)
CHANGE OF NAME
Recorded Jul 29, 2015
From: NYCOMED GERMANY HOLDING GMBH
To: TAKEDA GMBH
Reel/Frame 036205/0192 →
MERGER
Recorded Jul 28, 2015
From: TAKEDA GMBH
To: NYCOMED ASSET MANAGEMENT GMBH
Reel/Frame 036193/0178 →
MERGER
Recorded Jul 28, 2015
From: NYCOMED ASSET MANAGEMENT GMBH
To: NYCOMED GERMANY HOLDING GMBH
Reel/Frame 036201/0261 →
CHANGE OF NAME
Recorded Sep 4, 2007
From: ALTANA PHARMA AG
To: NYCOMED GMBH
Reel/Frame 019783/0625 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Sep 27, 2006
From: DUNKERN, TORSTEN; SCHUDT, CHRISTIAN; GRIMMINGER, FRIEDRICH; GHOFRANI, HOSSEIN ARDESCHIR; KAPS, MANFRED; ROSENGARTEN, BERNHARD
To: ALTANA PHARMA AG
Reel/Frame 018330/0502 →
Priority Claims (1)
EP 04100909
· Mar 5, 2004
· regional
Continuity (1)